Alberta resumes buying U.S. alcohol, months after pause meant to fight tariffs
Service Alberta Minister Dale Nally said Friday that the move signals a 'renewed commitment to open and fair trade' with the United States.
Smith said in March that the province would no longer buy U.S. alcohol and video lottery terminals, or sign contracts with American companies. Alberta's liquor stores are privately owned but must order stock through the provincial government.
ARTICLE CONTINUES BELOW
That came a day after U.S. President Donald Trump slapped heavy tariffs on Canadian goods and energy.
Other premiers also announced bans on U.S. liquor along with other proposed penalties.
Nally said in a statement that the decision to resume buying U.S. alcohol and gambling machines 'sets the stage for more constructive negotiations' ahead of a renewal of the Canada-U.S.-Mexico trade agreement.
The agreement, known as CUSMA, was negotiated during the first Trump administration and is up for a mandatory review in 2026.
'Prime Minister Mark Carney has made a clear effort to reset the relationship with the U.S. administration, and Alberta's government supports this approach,' Nally said.
'We are focused on highlighting Alberta's role as a responsible and collaborative trading partner and will continue working alongside other provinces to advocate for a tariff-free relationship.'
ARTICLE CONTINUES BELOW
ARTICLE CONTINUES BELOW
The minister said Albertans are encouraged to continue supporting local producers, even as more U.S. options return to store shelves.
In April, the province paused its policy around procurement from U.S. companies in what Nally called 'the spirit of diplomacy.'
This report by The Canadian Press was first published June 6, 2025.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
6 minutes ago
- Cision Canada
HLS Therapeutics Announces New Credit Agreement
TORONTO, Aug. 20, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that the company has entered into a new Credit Agreement (the "Agreement") with National Bank of Canada ("National Bank") as administrative agent which provides for committed credit facilities denominated in Canadian dollars of up to CAD $107 million (USD ~$77.5 million). National Bank serves as administrative agent and lead arranger, with the Toronto-Dominion Bank, Royal Bank of Canada, and Innovation Federal Credit Union as syndicate members. The Agreement replaced HLS's credit facility with JP Morgan Chase Bank, N.A. which had a maturity date of August 11, 2026. On closing, the proceeds from the new term facility were used to repay the Company's existing credit agreement in full. The new Agreement has a maturity date of August 19, 2029. The Agreement consists of a CAD $79 million term credit facility, a CAD $14 million delayed draw facility and a CAD $14 million revolving credit facility. In addition, HLS can increase facilities further through an uncommitted CAD $40 million accordion facility (subject to Lender agreement). Interest on the Agreement accrues at a rate per month equal to the sum of the Canadian Overnight Repo Rate Average ("CORRA") plus a range of 2.25% to 3.50% depending on the leverage ratio of the Company at the time. Interest rate spreads are 25-50 basis points below the rate in the Company's prior credit agreement, providing improved cash flow through reduced interest expense. The debt is denominated in Canadian dollars, creating a natural currency hedge against the Company's predominantly Canadian operations. In addition to the interest rate spread savings detailed above, HLS will achieve further interest rate savings in excess of 100 basis points based on current market interest rates, as a result of the differential between US dollar and Canadian dollar base rates. "We are pleased to finalize this new credit agreement with National Bank and our syndicate partners, which reflects their confidence in our outlook," said John Hanna, CFO of HLS Therapeutics. "The Agreement delivers improved terms that reflect our strengthened financial position and provides enhanced financial flexibility and cash flow to pursue our capital allocation priorities such as share buybacks and portfolio expansion." ABOUT HLS THERAPEUTICS INC. Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information visit: FORWARD LOOKING INFORMATION This release includes forward-looking statements regarding HLS and its business. Such statements are based on the current expectations and views of future events of HLS's management. In some cases the forward-looking statements can be identified by words or phrases such as "may", "will", "expect", "plan", "anticipate", "intend", "potential", "estimate", "believe" or the negative of these terms, or other similar expressions intended to identify forward-looking statements, including, among others, statements with respect to HLS's pursuit of additional product and pipeline opportunities in certain therapeutic markets, statements regarding growth opportunities and expectations regarding financial performance. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting HLS, including risks relating to the specialty pharmaceutical industry, risks related to the regulatory approval process, economic factors and many other factors beyond the control of HLS. Forward-looking statements and information by their nature are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause HLS's actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statement or information. Accordingly, readers should not place undue reliance on any forward-looking statements or information. A discussion of the material risks and assumptions associated with this release can be found in the Company's Annual Information Form dated March 12, 2025, and Management's Discussion and Analysis dated August 13, 2025, both of which have been filed on SEDAR+ and can be accessed at Accordingly, readers should not place undue reliance on any forward-looking statements or information. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and HLS undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. SOURCE HLS Therapeutics Inc.
Calgary Herald
19 minutes ago
- Calgary Herald
Posthase: Renters are spending a scary amount on housing
Article content Canadian renters are spending an ever-growing amount of their paycheques on rent, even though they may qualify for a mortgage. Article content Article content Nationally, they are spending 37.6 per cent of their income on rent, according to analysis from SingleKey Inc., falling just below the 40 per cent 'crisis' level. Article content But Toronto renters have already reached the crisis level by spending 41.1 per cent of their salaries on housing, or an average of $2,899 per month. Article content Article content The average rent in Canada is $2,200 per month, with Vancouver's $3,095 per month rate being the most expensive city for renters. Article content Article content It's no wonder renters have a hard time paying the bills. A recent Equifax Canada report said non-mortgage holders were twice as likely to miss a credit payment compared to those with a mortgage. Article content 'While the overall delinquency rate appears to be levelling off, the underlying story is far more complex,' Rebecca Oakes, vice-president of advanced analytics at Equifax Canada, said in a release. 'We continue to see a growing divide between mortgage and non-mortgage consumers, and continued financial strain among younger Canadians, who are facing a slower job market and rising costs.' Article content Overall, 1.4 million Canadians missed a credit payment in the second quarter of 2025, while consumer debt climbed to $2.58 trillion, Equifax said. Article content Article content This comes despite rents for condos and apartments falling 3.6 per cent year over year in July, marking the 10th consecutive month where Canada's rents have fallen year over year, according to data. Article content Article content The good news for renters is that it doesn't look like rent will be going up anytime soon. Article content 'The 3.6 per cent year-over-year rent decline in July is greater than the 2.7 per cent decline recorded in June and suggests that rent declines are likely to continue compounding,' said in its report. Article content Despite the challenges of paying their bills, many renters might still qualify for a mortgage. The average credit score among renters is 694, SingleKey said, which is above the 680 threshold needed for approval at many major banks.
Cision Canada
36 minutes ago
- Cision Canada
Veripath Partners Surpasses $500 Million in Assets Under Management and 140,000 Acres Under Stewardship, Marking 18 Years of Farmland Investment Excellence
CALGARY, AB, Aug. 20, 2025 /CNW/ - Omnigence Asset Management is pleased to recognize its partner fund, Veripath Partners, on achieving a major growth milestone: surpassing $500 million in assets under management (AUM) and stewarding more than 140,000 acres of Canadian farmland. This achievement coincides with the Veripath team's 18th anniversary as dedicated farmland investment managers. Since its inception, Veripath has been dedicated to identifying and acquiring high-quality farmland with a disciplined, data-driven approach. By focusing on productivity-adjusted pricing and long-term stewardship, the firm has delivered value to investors while maintaining a commitment to sustainable land management and operational best practices. "Reaching $500 million AUM and an 18-year team track record reflects both the material productivity adjusted price discounts of Canadian farmland and Veripath's consistent ability to execute," said Stephen Johnston, Director at Omnigence Asset Management. "Omnigence is proud to partner with Veripath in delivering a strategy that provides a strong value proposition and a stable, inflation-resilient return profile for investors" About Omnigence Asset Management: Omnigence Asset Management is a Canadian alternative investment platform specializing in farmland, operational private equity, and secondaries. With offices in Toronto and Calgary, the firm is committed to helping investors preserve purchasing power and build durable portfolios in a structurally challenging macro environment. Omnigence has grown to over CA$1 billion in platform assets by focusing on what it describes as the neglected middle, investment opportunities that are too small or too operationally complex for large institutions and traditional alternative managers. About Veripath Partners: Veripath Partners is a Canadian alternative investment firm focused exclusively on farmland. The firm currently manages a nationally diversified, Canadian focused row-crop fund with $500M+ AUM and 140,000+ acres. DISCLAIMER: Our reports, including this paper, express our opinions which have been based, in part, upon generally available public information and research as well as upon inferences and deductions made through our due diligence, research and analytical process. The information contained in this paper includes information from, or data derived from, public third party sources including industry publications, reports and research papers. Although this third-party information and data is believed to be reliable, neither Omnigence Asset Management nor its agents (collectively "Omnigence") have independently verified the accuracy, currency or completeness of any of the information and data contained in this paper which is derived from such third party sources and, therefore, there is no assurance or guarantee as to the accuracy or completeness of such included information and data. Omnigence and its agents hereby disclaim any liability whatsoever in respect of any third-party information or data, and the results derived from our utilization of that data in our analysis. While we have a good-faith belief in the accuracy of what we write, all such information is presented "as is," without warranty of any kind, whether express or implied. The use made of the information and conclusions set forth in this paper is solely at the risk of the user of this information. This paper is intended only as general information presented for the convenience of the reader and should not in any way be construed as investment or other advice whatsoever. Omnigence is not registered as an investment dealer or advisor in any jurisdiction and this report does not represent investment advice of any kind. The reader should seek the advice of relevant professionals (including a registered investment professional) before making any investment decisions. The opinions and views expressed in this paper are subject to change or modification without notice, and Omnigence does not undertake to update or supplement this or any other of its reports or papers as a result of a change in opinion stated herein or otherwise.
